▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Market Now

Samsung BioLogics cinches W15.7b CMO deal with European pharma

  • PUBLISHED :July 21, 2017 - 16:03
  • UPDATED :July 21, 2017 - 16:03
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[DISCLOSURE] Samsung BioLogics (207940) announced on July 21 that it has signed a 15.73 billion won (US$14.06 million) contract manufacturing deal with a European pharmaceutical company. 

This amounts to 5.34 percent of its 2016 revenue and the exclusive contract period will remain undisclosed until Dec. 31, 2019 to protect trade secrets. 

By Hwang You-mee (theinvestor@heraldcorp.com)

EDITOR'S PICKS